Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!

Eur Respir J. 2024 Oct 10;64(4):2401087. doi: 10.1183/13993003.01087-2024. Print 2024 Oct.

Authors

Laura C Price^{1

2}, Alex Lyon³, Kevin Boyd⁴

Affiliations

¹ National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK [email protected].
² NHLI Imperial College London, London, UK.
³ Cardiology, Royal Brompton Hospital, London, UK.
⁴ Haematology, Royal Marsden Hospital, London, UK.

PMID: 39389614
DOI: 10.1183/13993003.01087-2024

No abstract available

Publication types

Letter
Case Reports
Comment

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Female
Humans
Hypertension, Pulmonary / chemically induced
Hypertension, Pulmonary / drug therapy
Male
Middle Aged
Multiple Myeloma / drug therapy
Oligopeptides* / adverse effects
Pulmonary Arterial Hypertension* / chemically induced
Pulmonary Arterial Hypertension* / drug therapy

Substances

carfilzomib
Oligopeptides
Antineoplastic Agents